Treatment of hepatitis C: How will we use viral kinetics, response-guided therapy?

Current Gastroenterology Reports

Volumn 15, Issue 2, 2013, Pages

  Pawlotsky, Jean Michel ^a,b  

^a HENRI MONDOR HOSPITAL   (France)

^b INSERM U955   (France)

Author keywords

Antiviral therapy; HCV RNA; Real time PCR; Viral kinetics

Indexed keywords

BOCEPREVIR; PEGINTERFERON ALPHA; RIBAVIRIN; TELAPREVIR; VIRUS RNA;

ANALYTIC METHOD; ANTIVIRAL THERAPY; ARTICLE; DIAGNOSTIC KIT; DRUG INDICATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MEDICAL DEVICE; MONOTHERAPY; NONHUMAN; POLYMERASE CHAIN REACTION; RNA ANALYSIS; TRANSCRIPTION MEDIATED AMPLIFICATION; VIRUS CULTURE;

EID: 84872085171     PISSN: 15228037     EISSN: 1534312X     Source Type: Journal    
DOI: 10.1007/s11894-012-0309-x     Document Type: Article

References (32)

1. Chevaliez S, Rodriguez C, Pawlotsky JM. New virologic tools for management of chronic hepatitis B and C. Gastroenterology. 2012;142:1303-13.
2. Chevaliez S, Bouvier-Alias M, Brillet R, Pawlotsky JM. Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reactionbased method. Hepatology. 2007;46:22-31. (Pubitemid 47171917)
3. Chevaliez S, Bouvier-Alias M, Pawlotsky JM. Performance of the Abbott real-time PCR assay using m2000SP and m2000RT for hepatitis C virus RNA quantification. J Clin Microbiol. 2009;47:1726-32.
4. Chevaliez S, Bouvier-Alias M, Laperche S, Hezode C, Pawlotsky JM. Performance of version 2.0 of the Cobas AmpliPrep/Cobas TaqMan real-time PCR assay for hepatitis B virus DNA quantification. J Clin Microbiol. 2010;48:3641-7.
5. Paba P, Fabeni L, Perno CF, Ciotti M. Performance evaluation of the Artus hepatitis C virus QS-RGQ assay. J Virol Methods. 2012;179:77-80.
6. Chevaliez S, Bouvier-Alias M, Castera L, Pawlotsky JM. The Cobas AmpliPrep-Cobas TaqMan real-time polymerase chain reaction assay fails to detect hepatitis C virus RNA in highly viremic genotype 4 clinical samples. Hepatology. 2009;49:1397-8.
7. Vermehren J, Colucci G, Gohl P, et al. Development of a second version of the Cobas AmpliPrep/Cobas TaqMan hepatitis C virus quantitative test with improved genotype inclusivity. J Clin Microbiol. 2011;49:3309-15.
8. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2011;55:245-64.
9. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54:1433-44.
10. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335-74.
11. Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science. 1998;282:103-7. (Pubitemid 28471138)
12. Dahari H, Guedj J, Perelson AS, Layden TJ. Hepatitis C viral kinetics in the era of direct acting antiviral agents and IL28B. Curr Hepat Rep. 2011;10:214-27.
13. Lam NP, Neumann AU, Gretch DR, et al. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology. 1997;26:226-31. (Pubitemid 27280329)
14. Dahari H, Ribeiro RM, Perelson AS. Triphasic decline of hepatitis C virus RNA during antiviral therapy. Hepatology. 2007;46:16-21. (Pubitemid 47171916)
15. Silva M, Poo J, Wagner F, et al. A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE). J Hepatol. 2006;45:204-13.
16. Shudo E, Ribeiro RM, Perelson AS. Modelling the kinetics of hepatitis C virus RNA decline over 4 weeks of treatment with pegylated interferon alpha-2b. J Viral Hepat. 2008;15:379-82. (Pubitemid 351473634)
17. Bronowicki JP, Ouzan D, Asselah T, et al. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroenterology. 2006;131:1040-8. (Pubitemid 44515099)
18. Herrmann E, Lee JH, Marinos G, Modi M, Zeuzem S. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology. 2003;37:1351-8. (Pubitemid 36667315)
19. Chu TW, Kulkarni R, Gane EJ, et al. Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C. Gastroenterology. 2012;142:790-5.
20. Guedj J, Perelson AS. Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment duration. Hepatology. 2011;53:1801-8.
21. Zeuzem S, Buggisch P, Agarwal K, et al. The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. Hepatology. 2012;55:749-58.
22. Pawlotsky JM, Dahari H, Neumann AU, et al. Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology. 2004;126:703-14. (Pubitemid 38298318)
23. Dixit NM, Layden-Almer JE, Layden TJ, Perelson AS. Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature. 2004;432:922-4. (Pubitemid 40037156)
24. Hadziyannis SJ, Sette Jr H, Morgan TR, et al. Peginterferonalpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346-55.
25. Diago M, Shiffman ML, Bronowicki JP, et al. Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin. Hepatology. 2010;51:1897-903.
26. Moreno C, Deltenre P, Pawlotsky JM, et al. Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response: a meta-analysis. J Hepatol. 2010;52:25-31.
27. Ferenci P, Fried MW, Shiffman ML, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol. 2005;43:425-33. (Pubitemid 41111423)
28. Davis GL, Wong JB, McHutchison JG, et al. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology. 2003;38:645-52. (Pubitemid 37052151)
29. Berg T, von Wagner M, Nasser S, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology. 2006;130:1086-97.
30. Sanchez-Tapias JM, Diago M, Escartin P, et al. Peginterferonalfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology. 2006;131:451-60. (Pubitemid 44142452)
31. Ferenci P, Laferl H, Scherzer TM, et al. Peginterferon alfa-2a/ ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response. Gastroenterology. 2010;138:503-12.
32. Gane EJ, Stedman CA, Hyland RH, et al. Once daily PSI-7977 plus RBV: pegylated interferon alfa not required for complete rapid viral response in treatment-naive patients with HCV GT2 or GT3. Hepatology. 2011;54 Suppl 1:377A.